Servicios Personalizados
Revista
Articulo
Español (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por emailIndicadores
Citado por SciELO
Links relacionados
Similares en
SciELO
Compartir
Permalink
Revista Argentina de Salud Pública
versión impresa ISSN 1852-8724versión On-line ISSN 1853-810X
Resumen
LAGO, Manuel. Survival of adults hospitalized with COVID-19 and remdesivir: Bayesian re-analysis and meta-analysis of two clinical trials. Rev. argent. salud pública [online]. 2020, vol.12, suppl.1, pp.10-10. Epub 01-Oct-2020. ISSN 1852-8724.
INTRODUCTION
remdesivir is one of the numerous treatments evaluated against COVID-19, for which no effect on mortality has been reported. The objective of this review is to evaluate the effect of remdesivir on mortality in the first 28 days in patients hospitalized for COVID-19.
METHODS
a review was made in PubMed. Only randomized trials reporting 28-day mortality were selected. The treatment effect was evaluated using a fixed effect Bayesian model, and calculating the posterior distribution of relative risk (RR) and hazard ratio (HR).
RESULTS
two clinical trials were found that met the selection criteria. The probability of a combined RR of less than 1 in favor of remdesivir for mortality at 14 days was 98%, with an 95 % High Density credibility Interval (HDCrI 95%) [0.42 to 0.91], while, by re-analysis of Beigel's ACTT-1, the probability of a HR less than 1 in favor of remdesivir was 96%, with an HDCrI 95% [0.44 to 0.99].
CONCLUSION
both the meta-analysis of and the Bayesian re-analysis support the existence of a favorable effect of treatment with remdesivir in patients with COVID-19 pneumonia.
Palabras clave : COVID-19; Remdesivir; Mortality; Meta-analysis.
